Coloplast A/S

WBAG:COLO Stock Report

Market Cap: €26.9b

Coloplast Valuation

Is COLO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COLO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: COLO (€119.4) is trading below our estimate of fair value (€200.38)

Significantly Below Fair Value: COLO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COLO?

Key metric: As COLO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for COLO. This is calculated by dividing COLO's market cap by their current earnings.
What is COLO's PE Ratio?
PE Ratio39.7x
EarningsDKK 5.05b
Market CapDKK 200.37b

Price to Earnings Ratio vs Peers

How does COLO's PE Ratio compare to its peers?

The above table shows the PE ratio for COLO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average41.5x
COO Cooper Companies
55.1x23.0%US$19.8b
ALC Alcon
36.7x9.4%CHF 37.8b
7741 HOYA
35.5x11.6%JP¥7.0t
ALGN Align Technology
38.9x17.5%US$16.7b
COLO Coloplast
39.7x12.9%€200.4b

Price-To-Earnings vs Peers: COLO is good value based on its Price-To-Earnings Ratio (39.7x) compared to the peer average (41.5x).

Price to Earnings Ratio vs Industry

How does COLO's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
COLO 39.7xIndustry Avg. 28.9xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: COLO is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the European Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is COLO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COLO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate COLO's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COLO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€116.75
€122.49
+4.9%
11.0%€140.82€93.88n/a21
Oct ’25€117.55
€122.54
+4.2%
11.0%€142.18€93.89n/a20
Sep ’25€123.40
€122.17
-1.0%
11.3%€142.09€93.84n/a20
Aug ’25€119.75
€121.42
+1.4%
11.0%€142.07€95.16n/a20
Jul ’25€111.80
€120.02
+7.4%
10.5%€142.08€95.17n/a20
Jun ’25€110.60
€121.95
+10.3%
10.2%€142.06€95.16n/a19
May ’25€113.10
€122.93
+8.7%
10.9%€142.09€93.83n/a19
Apr ’25€123.85
€120.32
-2.9%
10.3%€142.13€93.86n/a19
Mar ’25€122.65
€116.96
-4.6%
10.1%€134.16€93.91n/a19
Feb ’25€107.20
€110.46
+3.0%
9.8%€129.01€84.62n/a19
Jan ’25€104.15
€109.56
+5.2%
10.3%€129.07€84.66n/a18
Dec ’24€105.95
€109.69
+3.5%
10.1%€129.05€84.65n/a18
Nov ’24€100.45
€113.71
+13.2%
9.2%€131.29€91.90€116.7518
Oct ’24€100.55
€116.05
+15.4%
9.9%€134.12€92.01€117.5517
Sep ’24€105.90
€121.79
+15.0%
10.1%€143.59€96.62€123.4015
Aug ’24€113.50
€124.66
+9.8%
9.9%€143.60€96.63€119.7516
Jul ’24€114.75
€122.90
+7.1%
11.0%€143.65€92.63€111.8016
Jun ’24€117.45
€122.95
+4.7%
11.0%€143.71€92.67€110.6016
May ’24€130.65
€122.53
-6.2%
10.0%€140.25€92.61€113.1016
Apr ’24€121.40
€121.15
-0.2%
9.8%€140.26€92.61€123.8516
Mar ’24€107.25
€121.26
+13.1%
10.2%€140.31€92.64€122.6515
Feb ’24€113.75
€121.99
+7.2%
9.7%€140.50€92.77€107.2015
Jan ’24€111.25
€123.56
+11.1%
7.7%€140.52€107.31€104.1515
Dec ’23€114.55
€126.00
+10.0%
11.4%€164.59€107.31€105.9514
Nov ’23€113.00
€127.41
+12.8%
12.2%€164.45€106.14€100.4514

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

emeis Société anonyme

€983.6m

Operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals.

ORP2

€6.02

7D

-7.3%

1Y

-98.7%

DENTSPLY SIRONA

US$3.6b

Manufactures and sells various dental products and technologies worldwide.

XRAY

US$17.41

7D

4.2%

1Y

-36.0%

Hologic

US$18.3b

Develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment.

HOLX

US$74.50

7D

-0.7%

1Y

13.5%